Dr. Gray Kueberuwa, DPhil.

Chief Executive Officer

At ImmunoKey, Gray is on a mission to revolutionise cancer treatment. Under his leadership, the company is developing the CARKey™ platform, a breakthrough technology that addresses the critical limitations of existing CAR T-cell therapies, offering hope to patients with solid tumours.

Gray has a background of a Masters in Biochemistry and a DPhil in oncolytic virotherapy from The University of Oxford, and a decade of experience in cell therapy development.

A proven biotech leader, Gray has experience of strategic leadership at all stages of the cell therapy development pathway including discovery research, intellectual property, process development, in-house and CDMO lentivirus and cell therapy GMP manufacturing in UK, France and Spain, regulatory filings with FDA and MHRA, clinical operations and clinical logistics. Gray has established research facilities from scratch, and built strong teams that have reliably generated novel T-cell therapies.